Clinical Phenotyping and Characterization of Neural Networks and Cognitive Processes Involved in Mental Retardation X-linked

NCT ID: NCT02854956

Last Updated: 2017-07-12

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 573 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-04-30
• Study Completion Date: 2018-03-31

Brief Summary

X-linked Mental retardation (XLMR) represent 10% of the causes of mental retardation with a prevalence in both sexes around 1/296, i.e. 3.3 / 1000 births (Opitz et al., 1986). This heterogeneous group of XLMR includes dozens of rare diseases, some of them affecting only a few patients. Molecular diagnosis is currently available in France for 25 XLMR genes, within the national network of XLMR molecular diagnosis. However, whereas some syndromes such as Fragile X syndrome, are now well clinically defined, this is not the case for recently identified syndromes for which very few data is available, preventing clinicians to focus molecular diagnosis on a specific gene.

Therefore, this study aims to :

• Achieve a description of the clinical phenotype specific to each XLMR gene (Phase 1 of the study, n=200)
• Characterize the cognitive learning mechanisms and dysfunctional neural networks involved (Phase 2 of the study, n=75, i.e. 5 groups of 15 patients with a mutation in the same gene). These two elements constitute key steps to develop appropriate rehabilitation strategies and targeted pharmacological therapies.

Moreover, the impact of mental retardation on the primary caregiver within the family and the induced burden in terms of psycho-social, organizational and economic burden will also be assessed. These elements, directly related to the patient's environment, are very important to characterize in order to better understand the consequences of each gene mutation (Phase 3 of the study, n=283). For example, it is necessary to better understand the impact of Fragile X syndrome in terms of capacity and behavior, lifestyle, and health care needs of the patients While advancing knowledge allows to consider innovative therapeutics, the implementation of these therapeutics and assessment of their impact on the patients' life trajectory, require precise characterization of the population to be treated in medico socioeconomic terms.

Conditions

X-linked Mental Retardation

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

X-linked Mental retardation

This is an observational study which will allow to precisely describe the phenotype associated to each X-linked mental retardation gene.

Group Type: OTHER

Neuropsychological, cognitive and behavioral assessment

Intervention Type: BEHAVIORAL

The assessment includes mainly :

• The Raven's Progressives matrices test which allow to assess the non-verbal reasoning mental age of the patient
• The Wechsler scale or Brunet Lézine scale which allow to assess The Intellectual Quotient
• The Peabody Picture Vocabulary Test Revised which allow to determine the Vocabulary age (receptive language).
• The Vineland adaptive behavioral scale which allow to assess the adaptive behavior
• The Nisonger child behavior rating form which allow to assess the behavior disorders
• Analogical visual reasoning task (eye-tracking assessment and behavior assessment) which allow to identify the strategy used to solve the task and provides an objective and quantitative assessment of visual analogical reasoning and cognitive inhibition.
• Kinematic analysis of a grasping movement which allow to study the effect of the orientation and the type of pinch on the movement duration and both the transport component and the grasp component.

Control Group

This group will be compared to X-linked mental retardation group in order to obtain a baseline on some cognitive tests.

Group Type: OTHER

Neuropsychological, cognitive and behavioral assessment

Intervention Type: BEHAVIORAL

The assessment includes mainly :

• The Raven's Progressives matrices test which allow to assess the non-verbal reasoning mental age of the patient
• The Wechsler scale or Brunet Lézine scale which allow to assess The Intellectual Quotient
• The Peabody Picture Vocabulary Test Revised which allow to determine the Vocabulary age (receptive language).
• The Vineland adaptive behavioral scale which allow to assess the adaptive behavior
• The Nisonger child behavior rating form which allow to assess the behavior disorders
• Analogical visual reasoning task (eye-tracking assessment and behavior assessment) which allow to identify the strategy used to solve the task and provides an objective and quantitative assessment of visual analogical reasoning and cognitive inhibition.
• Kinematic analysis of a grasping movement which allow to study the effect of the orientation and the type of pinch on the movement duration and both the transport component and the grasp component.

Interventions

Neuropsychological, cognitive and behavioral assessment

The assessment includes mainly :

• The Raven's Progressives matrices test which allow to assess the non-verbal reasoning mental age of the patient
• The Wechsler scale or Brunet Lézine scale which allow to assess The Intellectual Quotient
• The Peabody Picture Vocabulary Test Revised which allow to determine the Vocabulary age (receptive language).
• The Vineland adaptive behavioral scale which allow to assess the adaptive behavior
• The Nisonger child behavior rating form which allow to assess the behavior disorders
• Analogical visual reasoning task (eye-tracking assessment and behavior assessment) which allow to identify the strategy used to solve the task and provides an objective and quantitative assessment of visual analogical reasoning and cognitive inhibition.
• Kinematic analysis of a grasping movement which allow to study the effect of the orientation and the type of pinch on the movement duration and both the transport component and the grasp component.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Age : from 2 to 60 years old
• Having a pathogenic mutation of one of the X chromosome genes associated with :

• For boys : mental retardation (IQ<70), and/or developmental delay (DQ<70) and/or pervasive developmental disorder (autism, Asperger…)
• For girls : mental retardation (IQ<70), and/or developmental delay (DQ<70) and/or pervasive developmental disorder (autism, Asperger…) and/or specific learning disabilities

Exclusion Criteria

• patient or parents refusal to participate in the study
• genetic polymorphism in a X chromosome gene involved in mental retardation but not considered as pathogenic
• person refusing to be informed if an abnormality would be discovered during medical examination

• Minimum Eligible Age: 2 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Hospices Civils de Lyon

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Vincent DESPORTES, Pr

Role: PRINCIPAL_INVESTIGATOR

Groupement Hospitalier Est - Hôpital Femme Mère Enfant - Service de neurologie pédiatrique

Locations

Groupement Hospitalier Est - Hôpital Femme Mère Enfant - Service de neurologie pédiatrique

Bron, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Vincent DESPORTES, Pr

Role: CONTACT

vincent.desportes@chu-lyon.fr

(0)4 27 85 67 61 ext. +33

Sonia GALLETTI

Role: CONTACT

sonia.galletti@chu-lyon.fr

(0)4 27 85 77 39 ext. +33

Facility Contacts

Vincent DESPORTES, Pr

Role: primary

vincent.desportes@chu-lyon.fr

(0)4 27 85 67 61 ext. +33

Sonia GALLETTI

Role: backup

sonia.galletti@chu-lyon.fr

(0)4 27 85 77 39 ext. +33

Other Identifiers

2010-609

Identifier Type: -

Identifier Source: org_study_id